Keywords: AstraZeneca, Vaccine component, Astex, Alzheimer's drug candidate, BTG, CytoFab, Immune Design Corp, Sepsis

AstraZeneca in-licenses vaccine component; selects Alzheimer’s drug candidate from Astex accord; moves forward with BTG’s CytoFab

Article | 26 October 2010

Print This

In what was a busy couple of days for the Anglo-Swedish drug major, AstraZeneca (LSE: AZN), through its US subsidiary ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in